Ruthenium(ii)–arene complexes as anti-metastatic agents, and related techniques. Issue 1 (5th October 2021)

• Record Type: Journal Article
• Authors: Sonkar, Chanchal; Sarkar, Sayantan; Mukhopadhyay, Suman
• Is Part Of: RSC medicinal chemistry. Volume 13:Issue 1(2022)
• Page Start: 22
• Page End: 38
• Publication Date: 2021-10-05
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1039/d1md00220a
• Languages: English
• ISSNs: 2632-8682

Abstract

Abstract : Herein, we review the latest information on ruthenium(ii ) arene complexes that have shown anti-metastatic properties. We have also discussed about the targets of metastasis and the techniques used for these complexes, proving them as anti-metastatic agents. Abstract : With the discovery of cisplatin, a vast area of applications of metallodrugs in cancer treatment was opened but due to the side effects caused by the cisplatin complexes, researchers began to look for alternatives with similar anticancer properties but fewer side effects. Ruthenium was found to be a promising candidate, considering its significant anticancer properties and low side effects. Several ruthenium complexes, viz. NAMI-A, KP1019, KP1339, and TLD1433, have entered clinical trials. Some other arene ruthenium complexes such as RM175 and RAPTA-C have also entered clinical trials but very few of them have shown anti-metastatic properties. Herein, we provide information and probable mechanistic pathways for ruthenium(ii )–arene complexes that have been studied, so far, for their anti-metastatic activities. Also, we discuss the techniques and their significance for determining the anti-metastatic effects of the complexes.